Clinical Trial Update: An Open-label, First-in-Human, Dose-Escalation and Dose-Expansion Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPR1020 in Patients With Advanced Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Open-label, first-in-human dose-escalation and dose-expansion Phase I/II trial evaluating SPR1020 in patients with advanced solid tumors to assess safety, toler…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Solid Tumors

Drugs mentioned

• SPR1020

Snippet

Sponsor: Shanghai SciBrunch Therapeutics Co., Ltd. | Conditions: Advanced Solid Tumors, PARP Inhibitor | Phase 1, Phase 2 | Status: RECRUITING